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Abstract
Background: Cigarette smoking is a major risk factor in the development of age-related chronic obstructive pulmonary
disease (COPD). The serotonin transporter (SERT) gene polymorphism has been reported to be associated with COPD, and
the degree of cigarette smoking has been shown to be a significant mediator in this relationship. The interrelation between
circulating serotonin (5-hydroxytyptamine, 5-HT), cigarette smoking and COPD is however largely unknown. The current
study aimed at investigating the mediation effects of plasma 5-HT on cigarette smoking-induced COPD and the relation
between plasma 5-HT levels and age.
Methods: The association between plasma 5-HT, age and COPD was analyzed in a total of 62 COPD patients (ever-smokers)
and 117 control subjects (healthy non-smokers and ever-smokers). Plasma 5-HT levels were measured by enzyme-linked
immuno assay (EIA).
Results: The elevated plasma 5-HT levels were significantly associated with increased odds for COPD (OR=1.221, 95%
CI=1.123 to 1.319, p,0.0001). The effect remained significant after being adjusted for age and pack-years smoked
(OR=1.271, 95% CI=1.134 to 1.408, p=0.0003). Furthermore, plasma 5-HT was found to mediate the relation between
pack-years smoked and COPD. A positive correlation (r=0.303, p=0.017) was found between plasma 5-HT levels and age in
COPD, but not in the control subjects (r=20.149, p=0.108).
Conclusion: Our results suggest that cigarette smoke-induced COPD is partially mediated by the plasma levels of 5-HT, and
that these become elevated with increased age in COPD. The elevated plasma 5-HT levels in COPD might contribute to the
pathogenesis of this disease.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by a progressive, nearly irreversible airflow obstruction and an
abnormal inflammatory response in the lung [1]. The pathological
changes of COPD include emphysema and/or bronchitis [2].
Diagnosis of COPD is based on spirometry which is measured by
the ratio of force expiratory volume in 1 second (FEV1) to force
volume capacity (FVC; FEV1/FVC) [3]. FEV1 alone reflects the
severity of the disease [4]. COPD is predicted to become the third
leading cause of death by 2020 [5], and yet there is no effective
treatment. The risk of developing COPD grows with age, while
the aging population is one of the major concerns around the
world. According to the U.S. Census Bureau international
database released in 2002, the proportion of the population aged
65 and above will constitute more than 20% of the total
population in developed countries by 2025 [6]. Therefore, it is
important to investigate possible predictors in order to prevent the
disease at an early stage. One Hong Kong-based study has shown
that smoking is an important predictor of COPD [7]. However,
exploring other factors is necessary in order to gain a better
understanding of the etiology of the disease.
Serotonin (5-hydroxytyptamine, 5-HT) is a neurotransmitter
that plays an important role in pulmonary function. Reduction of
plasma 5-HT levels has been associated with age in an in vivo study
[8]. Current studies on the association between 5-HT and COPD
focus mainly on the polymorphism of the serotonin transporter
gene and pulmonary hypertension [9]. The serotonin transporter
(SERT) is a membrane bound protein that controls the transport
of 5-HT and has been shown to regulate plasma 5-HT levels [10].
The severity of pulmonary hypertension was positively associated
with the frequency of the L-allele of the SERT gene in COPD
[11]. A genome-wide association study (GWAS) based on more
than 20,000 Europeans has demonstrated five loci that are
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receptor 4 (5-HTR4) [12]. More recently, Ishii and colleagues
suggest that the degree of cigarette smoking may partially mediate
the relation between SERT gene (SLC6A4) variation and COPD
pathogenesis [13]. However, the interrelation between smoking,
circulating 5-HT levels and COPD is still unclear.
On the basis of these previous findings, we hypothesized that
plasma 5-HT contributes to the development of cigarette smoke-
induced COPD. The present study aimed at investigating the
mediation effects of plasma 5-HT levels on the relation between
pack-years smoked and COPD, and at studying the correlation
between plasma 5-HT levels and age in the COPD patients as well
as in the control subjects.
Materials and Methods
Ethics statement
This study was approved by the Ethics Committee of
Institutional Review Board of the University of Hong Kong/
Hospital Authority Hong Kong West Cluster (HKU/HA HKW
IRB, UW 04-058 T/380) and all participants provided written
informed consent.
Study design
This study followed the STROBE-guidelines (strengthen the
reporting of observational studies in epidemiology) [14]. Pulmo-
nary function parameters were measured according to the
American Thoracic Society guidelines [15]. The pre-bronchodi-
lator FEV1 and FVC values (% predicted) were used in this study.
The reference values were based on our local population [16]. All
COPD patients showed limited (,10% FEV1 % predicted)
reversibility after the application of the bronchodilator. Informa-
tion such as smoking habits, pack-years smoked, respiratory
symptoms and other diseases were obtained by questionnaire.
Subjects with a history of asthma, other airway diseases or
ischemic heart disease were excluded.
Participants
One hundred and seventy-nine male subjects were randomly
selected from the COPD database conducted by the COPD Study
Group of the Hong Kong Thoracic Society between 2005 and
2006 [7]. Stable COPD patients were recruited from out-patient
respiratory clinics and defined according to the COPD guideline
published in the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) [4], with FEV1/FVC,70 and/or FEV1,80 (%
predicted) and no exacerbation in the past 12 weeks prior to the
recruitment. They were either current smokers or ex-smokers
(defined as those who have not smoked for at least one year).
Control subjects were recruited from churches and community
centers for the elderly in Hong Kong. They were subdivided into
healthy non-smokers and ever-smokers, including current and ex-
smokers. They were defined as control subjects by a measurement
of FEV1/FVC$70 and FEV1$80 (% predicted) and had no
chronic respiratory symptoms.
Preparation of platelet poor plasma and 5-HT
measurement
The venous blood samples obtained from all subjects were
centrifuged at 16006ga t4 uC for 10 minutes. The platelet poor
plasma was carefully collected and stored at 280uC until further
analysis. Plasma 5-HT levels were measured using commercially
available enzyme-linked enzyme-linked immuno assay (EIA) kits
(Enzo Life Sciences, Plymouth Meeting, USA). The detection
range of the kit was 0.49–500 ng/ml.
Statistical analysis
Values are expressed as mean 6 SD for normally distributed
variables and median (interquartile range [IQR]) for non-normally
distributed variables. Normality was tested by the Kolmogorov-
Smirnov test. Demographic data and 5-HT levels between the two
groups were compared by the two-tailed independent Student’s t-
test, the Mann-Whitney U test or the x
2 statistics, where
appropriate. The regression and mediation analyses were
performed within healthy ever-smokers and COPD patients, since
all of our COPD patients are ever-smokers.
Binary logistic regression analysis was applied to estimate the
strength of association between the risk of developing COPD and
plasma 5-HT levels, odds ratios (OR) with 95% confidence
intervals (CI) were calculated (before and) after adjusting for age
and pack-years smoked.
Mediation analysis with dichotomous outcomes was implement-
ed to identify the potential mediating effect of plasma 5-HT levels
on the relation between pack-years smoked and COPD, based on
the procedures described by Herr [17]. Briefly, the total effect of
pack-years smoked (i.e. initial variable) on COPD occurrence (i.e.
outcome) was expressed as the sum of their direct and indirect
effects. The indirect effect was obtained from the product of the
effect of pack-years smoked (i.e. initial variable) on plasma 5-HT
Table 1. Characteristics of study subjects.
Healthy non-smokers Healthy ever-smokers COPD ever-smokers
Sample size 52 65 62
Age 57.6619.5 64.4615.0
bc72.866.9
Smoking status (Current/ex-smoker) — 22/43 22/40
Pack-years smoked (Missing value %) — 24.9617.4 (10.8)
c54.7637.1
FEV1, % predicted 102.4612.0 101.2611.2
bc37.8612.8
FVC, % predicted 100.5610.8 100.7610.5
bc66.5618.5
FEV1/FVC 79.265.8
a76.365.4
bc41.669.1
Values are mean 6 SD.
FEV1=force expiratory volume in one second, FVC=force vital capacity.
ap,0.01 compared to healthy non-smokers.
bp,0.001 compared to healthy non-smokers.
cp,0.001 compared to healthy ever-smokers.
doi:10.1371/journal.pone.0031617.t001
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COPD occurrence (i.e. the outcome), while controlling for the
pack-years smoked. The total, direct and indirect effects were
obtained from the coefficients of different regression models. Since
plasma 5-HT levels were not normally distributed, a log-
transformation of this variable was performed in the linear
regression model. The significance of the indirect mediation effect
was determined using the Sobel test [18]. All the regression
analyses performed for computing the regression coefficients for
the mediation analysis were adjusted for age. Missing values were
handled by excluding cases list-wise for all regression analyses.
Spearman’s correlation analysis was applied to study the
relation between age and plasma 5-HT levels. The Statistical
Package for the Social Sciences (SPSS/PASW, version 18.0,
Chicago, IL, USA) was used for statistical analyses. A p-value of
less than 0.05 was regarded statistically significant.
Results
Subject demographics
The demographic characteristics of all studied subjects were
summarized in Table 1. Stable COPD patients were significantly
older than healthy non-smokers or ever-smokers. The number of
pack-years smoked was significantly higher in the COPD patients
than in healthy ever-smokers. There were missing data with
respect to the pack-years smoked (10.8%) in healthy ever-smokers
due to incomplete information in the questionnaires. The COPD
patients had significantly lower lung function (FEV1 % predicted,
FVC % predicted and FEV1/FVC ratio) compared to the control
subjects.
Plasma levels of 5-HT
The plasma 5-HT levels were significantly higher in the COPD
patients (96.6 ng/ml [43.6–209.8]; median [IQR]) than in either
healthy non-smokers (32.4 ng/ml [24.2–54.9]) or ever-smokers
(41.4 ng/ml [28.5–62.9], Figure 1A). We subdivided the three
study groups into two subgroups of participants younger than 65
and those aged 65 or older, using the 65 year-mark as the cut-
point. In those younger than 65 years of age, we found that plasma
5-HT levels were significantly higher in healthy ever-smokers
(n=25, 55.5 ng/ml [33.7–67.7]) than in healthy non-smokers
Figure 1. Plasma 5-HT levels across COPD patients and control
subjects. (A) Plasma 5-HT levels of healthy non-smokers (NS), healthy
ever-smokers (S) and COPD ever-smokers (COPD S). (B) Plasma 5-HT
levels of healthy non-smokers (NS), healthy ever-smokers (S) and COPD
ever-smokers (COPD S) in those ,65 years old and $65 years old. Solid
horizontal line represents the median value. P values were obtained
from the Mann-Whitney U test.
doi:10.1371/journal.pone.0031617.g001
Figure 2. Plasma 5-HT levels of COPD patients with different
stages. Solid horizontal line represents the median value. No
significant difference was found across the groups.
doi:10.1371/journal.pone.0031617.g002
Figure 3. Preliminary findings on the plasma 5-HT levels of
COPD non-smokers and control subjects. Plasma 5-HT levels of
healthy non-smokers (NS) and COPD non-smokers (COPD NS). Solid
horizontal line represents the median value. P values were obtained
from the Mann-Whitney U test.
doi:10.1371/journal.pone.0031617.g003
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COPD ever-smokers in this subgroup (n=5, 77.7 ng/ml [53.1–
195.8]) were significantly higher than those of healthy non-
smokers, and higher than those of healthy ever-smokers at
borderline level. In those 65 or over, the plasma 5-HT levels
were significantly higher in COPD ever-smokers (n=57, 97.6 ng/
ml [43.4–213.6]) than in either healthy non-smokers (n=29,
35.5 ng/ml [23.9–58.3]) or healthy ever-smokers (n=40, 37.2 ng/
ml [21.7–61.1], Figure 1B). There were no significant differences
in plasma 5-HT levels across COPD severity (Figure 2). In another
subgroup analysis with limited sample size, our preliminary data
showed that the plasma 5-HT levels of COPD non-smokers (n=5,
86.5 ng/ml [42.0–120.4] were also significantly higher than those
of healthy non-smokers (Figure 3).
Since 5-HT levels are reported to correlate negatively with
blood pressure [19], we examined the plasma 5-HT levels in
COPD patients with or without hypertension. There were 15
COPD patients with hypertension in this cohort. In the subgroup
analysis, there was no significant difference (p=0.96) in the plasma
levels of 5-HT between COPD patients with (106.2 ng/ml [65.5–
181.7]) and those without hypertension (5-HT: 94.8 ng/ml [43.0–
217.3], data not shown). Therefore, we included subjects with
hypertension in all the analyses in this study.
Association between plasma 5-HT levels and COPD
The risk of developing COPD was analyzed by including
plasma 5-HT levels, age, and pack-years smoked in the binary
logistic regression model. The odds ratios were calculated
according to a 10-units change of 5-HT levels. Plasma 5-HT
levels were significantly associated with an increased odds for
COPD (OR=1.221, 95% CI=1.123 to 1.319, unadjusted). This
association remained significant after adjusting for age and pack-
years smoked (OR=1.271, 95% CI=1.134 to 1.408, Table 2).
Mediation effects of 5-HT on the relation between pack-
years smoked and COPD
We found a significant association between pack-years smoked
and COPD. Pack-years smoked were also significantly associated
with plasma 5-HT levels. The mediation effect of plasma 5-HT
levels on the relation between pack-years smoked and COPD was
found to be significant (p=0.035) using the Sobel test. Also, the
direct effect of pack-years smoked on COPD was significant
(p=0.001) in the presence of plasma 5-HT, indicating a partial
mediation effect of plasma 5-HT levels on the degree of smoking
and the development of COPD (Table 3).
Correlation between plasma 5-HT levels and age
In the control subjects (healthy non-smokers and ever-smokers),
we found no significant correlation between plasma 5-HT levels
and age (r=20.149, p=0.108). In the COPD patients however,
plasma 5-HT levels were positively associated with age (r=0.303,
p=0.017). In the subgroup analysis, there was no association
between plasma 5-HT levels and age in healthy non-smokers
(r=20.024, p=0.863), but a negative association in healthy ever-
smokers (r=20.330, p=0.007) (Figure 4). Since the COPD
patients are significantly older than the control subjects, we tried to
match the age between control subjects and COPD patients with
$65 years of age and performed the correlation analysis again.
There was still no correlation between plasma 5-HT and age in
the control subjects (healthy non-smokers and ever-smokers)
(r=20.128, p=0.295, n=69), but a significant positive correla-
tion in the COPD patients (r=0.344, p=0.009, n=57) (data not
shown).
Discussion
This is the first report to demonstrate the association between
plasma 5-HT levels, age, and COPD. Higher plasma 5-HT levels
were found in stable COPD patients compared to the control
subjects, which did, however, not correlate with the severity of the
disease. Plasma 5-HT was a significant mediator of the relation
between pack-years smoked and COPD. We also demonstrated a
positive correlation between plasma 5-HT levels and age in the
COPD patients, but not in the control subjects.
Platelet activation is one of the mechanisms that induce the
release of 5-HT into the circulating blood. Nicotine, a major
component in cigarette smoke, has been reported to stimulate the
Table 2. Association between plasma levels of 5-HT and
COPD in ever smokers with or without COPD by binary logistic
regression analysis.
a95% CI
aOR
aSE Lower bound Upper bound
bP value
5-HT (Unadjusted) 1.221 0.098 1.123 1.319 ,0.0001
5-HT (
cAdjusted) 1.271 0.137 1.134 1.408 0.0003
OR=odds ratio, SE=standard error, CI=confidence interval.
aCorresponding to a 10-unit change of the plasma 5-HT level.
bAccording to Wald test.
cAdjusted for age and pack-years smoked.
doi:10.1371/journal.pone.0031617.t002
Table 3. Mediation effects of 5-HT on the relation between pack-years smoked and COPD.
Effect Estimate SE P value
Initial: Pack-years smoked
aTotal: Pack-years smoked on COPD 0.050 0.011 0.000
Mediator: Serotonin (5-HT)
bPack-years smoked on 5-HT 0.008 0.003 0.003
Outcome: COPD
c5-HT on COPD given pack-years smoked 0.024 0.007 0.000
dIndirect: Pack-years smoked on COPD through 5-HT 0.483 0.046 0.035
eDirect: Pack-years smoked on COPD given 5-HT 0.046 0.014 0.001
Since the level of 5-HT was not normally distributed, a log-transformation was performed in the linear regression model. All analyses were adjusted for age.
SE=standard error.
a,b,c,eRegression analyses were performed to calculate parameter estimates.
dThe estimate is the product of the estimates of b and c. After the estimate and SE of the product were calculated, the Sobel test was performed to assess the
significance of the indirect effect.
doi:10.1371/journal.pone.0031617.t003
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with the literature, we found significant higher plasma 5-HT levels
in healthy ever-smokers compared to those of healthy non-smokers
with ,65 years of age. Such difference disappeared in those $65
years of age, which might be due to the lowering effect of plasma
5-HT levels in ever-smokers with an increase in age. One possible
mechanism for the elevated plasma 5-HT levels in COPD patients
is the persistent platelet activation found in patients with stable or
acute exacerbation of COPD [21]. Increased plasma 5-HT levels
might be taken up by platelets via SERT. That way, SERT would
be modified and downregulated due to the increased intracellular
5-HT levels in platelets, resulting in the inhibition of 5-HT
reuptake [22]. These processes might further increase the plasma
5-HT levels in COPD.
Plasma 5-HT levels have been shown to be correlated with
clinical severity and pulmonary function in symptomatic asthma
patients [23]. In contrast, we found no association between plasma
5-HT levels and disease severity in COPD patients. This
discrepancy may be due to the fact that the pathogenesis between
asthma and COPD is different [24]. Another possible reason is
that all the COPD patients in this study are stable. Here, we
reported the partial mediation effect of plasma 5-HT on the
relation between pack-years smoked and COPD. Ishii and
colleagues have shown that cigarette smoking is a significant
mediator of the relation between SERT polymorphism and
COPD [13]. Whether the increased plasma 5-HT levels in COPD
patients are due to SERT gene polymorphism remains unclear. In
a small group of male COPD non-smokers, significant higher
plasma 5-HT levels were observed in comparison to healthy non-
smokers, suggesting that the plasma 5-HT levels are influenced by
other factors apart from cigarette smoking (Figure 5). For example,
COPD comorbidities such as increased pulmonary artery pressure
or vascular dementia might be associated with the high plasma 5-
HT levels [25–26]. Further studies are required to shed more light
on these contributing factors and their possible role in altering
plasma 5-HT levels in patients with COPD.
Figure 4. Spearman’s correlation between plasma 5-HT levels
and age in different groups. The scatter plot of the relation
between plasma 5-HT levels and age in healthy non-smokers (A),
healthy ever-smokers (B) and COPD ever-smokers (C). The Spearman
correlation coefficient (r) and the p value were shown.
doi:10.1371/journal.pone.0031617.g004
Figure 5. Hypothetic diagram for the relation among SERT
gene polymorphism, plasma 5-HT, pack-years smoked and
COPD. Pack-years smoked exert both direct and mediation effects on
COPD.
doi:10.1371/journal.pone.0031617.g005
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study using different components of blood [27], demonstrating no
correlation between plasma 5-HT levels and age, regardless of
gender and smoking status. These findings are in agreement with
the results obtained from our control subjects (healthy non-
smokers and ever-smokers). However, their subjects were much
younger (36.0611.5) than our control subjects, and the effect of
gender on the association between 5-HT and age was not
addressed in the study. Another study reports a negative
correlation between plasma 5-HT levels and age in women with
age ranging from 40–84 years [28], regardless of smoking status,
similar to male healthy ever-smokers in this study. Since there was
no significant difference in age between healthy non-smokers and
ever-smokers in our samples, our data suggest that healthy ever-
smokers may be able to maintain the homeostasis of circulating 5-
HT by lowering its level with an increase in age. In contrast, we
found a positive correlation between plasma 5-HT levels and age
in COPD ever-smokers. These data suggest that the regulation of
plasma 5-HT levels is disturbed in COPD patients. A disturbance
in any of the regulatory processes of 5-HT, including uptake,
storage, release and breakdown by monoamine oxidases (MAOs)
in the aging process or during the development of COPD can
result in changes in the plasma levels of 5-HT.
The lung is a site at which the reuptake and removal of
circulating 5-HT takes place. Different components of cigarette
smoke have been shown to reduce MAOs’ activity in the lung [29–
32]. An inhibition of the reuptake and removal of 5-HT may lead
to the accumulation of 5-HT in the pulmonary vasculature, a
process believed to be involved in the pathogenesis of lung disease
[33], including COPD.
Limitations
The present study has significant limitations. Firstly, it is a cross-
sectional study and thereby does not allow for the conclusion of a
causal link between 5-HT and the presence of COPD. Prospective
cohort studies on healthy smokers are therefore required to fully
address the role of 5-HT in the development and progression of
COPD. Secondly, all measurements were carried out in plasma,
which reflects only systemic changes and may not adequately
reflect the local concentrations in the lungs. Further studies
involving biological samples such as bronchoalveolar lavage (BAL),
induced sputum and exhaled breath condensate, might shed more
light on the local pulmonary processes. Thirdly, the comparison of
plasma 5-HT levels between healthy non-smokers and COPD
non-smokers was limited by the small sample size; furthermore,
the large difference in sample size between the two groups may not
provide a fair comparison. The age difference between COPD
patients and control subjects is another limitation in this study. To
ensure our results were not due to the age difference between the
two groups, age was entered as a covariant in the regression
analyses.
Conclusion
Our results demonstrated the elevation of plasma 5-HT levels in
COPD patients, which is a significant mediator of the relation
between cigarette smoking and the presence of COPD. We
speculate that the cigarette smoke-mediated injury in COPD lungs
is partially mediated by plasma 5-HT levels. Both cigarette
smoking and COPD affected the association between plasma 5-
HT levels and age. Our findings further support the involvement
of the serotoninergic system in the pathogenesis of COPD. Further
investigation of the functional role and the regulation of 5-HT in
COPD is important for understanding and preventing the
progression of this disease.
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